Unit 2, 22nd Floor, Tower 6789, 6789 Ayala Avenue, Makati City

+63 28887 5160

HCP Portal Login
a

News & Events

News
Events
Position and Policy Regarding Reduction of the Investment Unit of the Company’s Shares

Position and Policy Regarding Reduction of the Investment Unit of the Company’s Shares

For Print (PDF) Company Name: Eisai Co., Ltd. Representative: Haruo Naito Representative Corporate Officer and CEO (Code 4523 Tokyo Stock Exchange Prime Market) Inquiries: Sayoko Sasaki Vice President, Corporate Communications Phone +81-3-3817-5120   1.  Position Regarding Reduction in Trading Unit (Position to shift to the level of less than 500,000 yen) Eisai Co., Ltd. (the Company) understands that […]

Newsletter
June 29, 2023
Read more
EISAI’S “NOUKNOW®” WILL CONTINUE TO BE UTILIZED FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2023 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY

EISAI’S “NOUKNOW®” WILL CONTINUE TO BE UTILIZED FOR BRAIN HEALTH ASSESSMENT AS PART OF THE FY2023 DEMENTIA EXAMINATION PROJECT BY TOKYO BUNKYO CITY

ACHIEVEMENT OF OUTCOME INDICATORS IN FY2022 PAY FOR SUCCESS CONTRACT For Print (PDF) Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that brain health checks utilizing “NouKNOW®” (pronounced “NOH-NOH”), Eisai’s digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by […]

Newsletter
June 22, 2023
Read more
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease The PDUFA action date for traditional approval of LEQEMBI has been set for July 6, 2023, with designation of priority review LEQEMBI received accelerated approval from […]

Newsletter
June 10, 2023
Read more
EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE IN SOUTH KOREA

EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE IN SOUTH KOREA

For Print (PDF) TOKYO and CAMBRIDGE, Mass., June 8, 2023 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai has submitted a marketing authorization application for lecanemab (brand name in the U.S.: LEQEMBI®), an investigational anti-amyloid beta (Aβ) […]

Newsletter
June 8, 2023
Read more

Showing 52 of 104

1 … 11 12 13 14 15 … 26

FAQs

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Your Title Goes Here

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Our Values

Values are an integral part of our foundation. With every decision, we ensure that we follow:

Integrity

Integrity is the living up to legal, moral and ethical principles in the conduct of HI-Eisai Pharmaceutical Inc. business. It means that each employee embodies the value of integrity, and therefore represents the company in honesty and rectitude in all the ways they do their work.

It is expected that each employee would make decisions guided by good judgement, not just for one‘s self, but for HI-Eisai as the company. An employee who acts with integrity ensures that he has understanding of the principles by which the company operates, and in situations where he lacks clarity, will actively seek guidance.

Respect

The company is committed to ensure that it maintains a safe, inclusive, and healthy working environment that promotes productivity among employees. All employees are expected to show respect to fellow employees, customers, and patients, regardless of differences in gender, culture, backgrounds, and beliefs. Leaders in the organization are likewise expected to promote inclusivity with their teams, and shall not tolerate any discriminatory and offensive actions.

Accountability

Accountability at work means assuming responsibility for the business outcome and how that is achieved. It means that every employee, in whichever position, are equally responsible for the decisions and actions they make for the company. It is likewise, the responsibility of each employee to report, any knowledge of misconduct or potential violation to the company‘s rules and regulations.

Patient-Centric

At the heart of the company‘s operation are the patients. This means that every decision to be made, considers the potential impact and benefit to the patients. As such, the company commits itself in ensuring that business objectives align with its principle of human health care or hhc. The programs created and implemented are based on how well they could contribute to improving patients‘ lives.

For field-based employees, being patient-centric means that the focus of engagements with customers are on understanding patient needs as well as providing these stakeholders with comprehensive information on how HI-Eisai‘s products can support their patients goals.

For each employee, being patient-centric means taking on their responsibilities with care and consideration on how it impacts the patients experience, be it by making relevant information readily available for the doctors; or by ensuring access and availability to the medicines we offer.

Excellence

As a patient-centric company, we define Excellence by the outstanding quality of our work to improve patients‘ lives. Each employee is expected to consistently demonstrate work ethics that align to our values, policies, and our desire to provide above standard service. The company is committed in ensuring that all actions are in compliance with legal requirements.

Being excellent means that every employee passionately strives to be better and participates in the company‘s initiatives to develop their members in terms of knowledge, skills, and behavior, which will support a continuously improving, responsible and performance-driven workforce.

Our Vision

To be a successful and sustainable business in the Philippines by driving innovation and providing solutions to address unmet healthcare needs fueled by high-performing employees who deliver meaningful value and experience to patients and their families.

Our Mission

We give first thought to patients and their families, and to increasing the benefits health care provides.

Unit 2, 22nd Floor, Tower 6789, 6789 Ayala Avenue, Makati City

+63 28887 5160